Allan Young, J. Rucker, Vincent Van den Eynde, Charles Redhead, B. Barnett, Lila Godet, A. Cleare, John Cosgrove, S. Stahl, T. Birkenhäger, P. K. Gillman
{"title":"关于使用经典单胺类氧化酶抑制剂治疗抑郁症的专家圆桌讨论——第一部分","authors":"Allan Young, J. Rucker, Vincent Van den Eynde, Charles Redhead, B. Barnett, Lila Godet, A. Cleare, John Cosgrove, S. Stahl, T. Birkenhäger, P. K. Gillman","doi":"10.3928/00485713-20230717-01","DOIUrl":null,"url":null,"abstract":"\n Experienced clinicians and academics from the International MAOI (monoamine oxidase inhibitor) Expert Group comment on questions of interest concerning MAOI pharmacotherapy for depression, especially as they pertain to the illustrative case summaries presented in this part one of the Expert Roundtable Discussion. These comments focus on practical therapeutics and aspects of difficult cases that guidelines simply do not, and cannot, address, such as the important fact that psychotic depression may respond rapidly to MAOIs. The ethical and medico-legal issues relating to cost and ongoing availability are also discussed.\n \n [\n Psychiatr Ann\n . 2023;53(8):359–363.]\n \n","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One\",\"authors\":\"Allan Young, J. Rucker, Vincent Van den Eynde, Charles Redhead, B. Barnett, Lila Godet, A. Cleare, John Cosgrove, S. Stahl, T. Birkenhäger, P. K. Gillman\",\"doi\":\"10.3928/00485713-20230717-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n Experienced clinicians and academics from the International MAOI (monoamine oxidase inhibitor) Expert Group comment on questions of interest concerning MAOI pharmacotherapy for depression, especially as they pertain to the illustrative case summaries presented in this part one of the Expert Roundtable Discussion. These comments focus on practical therapeutics and aspects of difficult cases that guidelines simply do not, and cannot, address, such as the important fact that psychotic depression may respond rapidly to MAOIs. The ethical and medico-legal issues relating to cost and ongoing availability are also discussed.\\n \\n [\\n Psychiatr Ann\\n . 2023;53(8):359–363.]\\n \\n\",\"PeriodicalId\":20917,\"journal\":{\"name\":\"Psychiatric Annals\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatric Annals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/00485713-20230717-01\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatric Annals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/00485713-20230717-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One
Experienced clinicians and academics from the International MAOI (monoamine oxidase inhibitor) Expert Group comment on questions of interest concerning MAOI pharmacotherapy for depression, especially as they pertain to the illustrative case summaries presented in this part one of the Expert Roundtable Discussion. These comments focus on practical therapeutics and aspects of difficult cases that guidelines simply do not, and cannot, address, such as the important fact that psychotic depression may respond rapidly to MAOIs. The ethical and medico-legal issues relating to cost and ongoing availability are also discussed.
[
Psychiatr Ann
. 2023;53(8):359–363.]
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
